Monitoring and treatment of Wilson disease: progress and challenges
- PMID: 36183739
- DOI: 10.1016/S2468-1253(22)00284-9
Monitoring and treatment of Wilson disease: progress and challenges
Conflict of interest statement
VM has received a research grant from Arbormed; received consulting fees and payments for manuscript writing from Alexion Pharmaceuticals; participated on the advisory board for Alexion Pharmaceuticals; and been invited to the advisory board for Orphalan. MCH declares no competing interests.
Comment on
-
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1092-1102. doi: 10.1016/S2468-1253(22)00270-9. Epub 2022 Sep 30. Lancet Gastroenterol Hepatol. 2022. PMID: 36183738 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
